Preferred Label : teriflunomide;

MeSH note : a leflunomide metabolite;

CISMeF synonym : HMR1726;

MeSH synonym : (Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide; (2Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide;

MeSH Hyperonym : 2-hydroxyethylidene-cyanoacetic acid-4-trifluoromethyl anilide;

MeSH hyponym : HMR-1726; A 1726; A771726; A-771726; A77 1726;

MeSH Related Number : 108605-62-5;

Is substance : O;

UNII : 1C058IKG3B;

InChIKey : UTNUDOFZCWSZMS-YFHOEESVSA-N;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-marr/teriflunomide
2024
false
false
false
France
French
administration, oral
risk reduction
patients guideline
handbooks
pregnancy
teratogens
teriflunomide
risk management
contraception
Contraindications, Drug
breast feeding
Chemical and Drug Induced Liver Injury
continuity of patient care
multiple sclerosis, relapsing-remitting
leukopenia
hypertension
opportunistic infections
teriflunomide
crotonates
toluidines
crotonates
toluidines

---
https://www.ema.europa.eu/en/medicines/human/EPAR/teriflunomide-accord
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
teriflunomide
teriflunomide
drugs, generic
multiple sclerosis, relapsing-remitting
child
adolescent
drug approval
europe
administration, oral
teriflunomide
immunosuppressive agents
immunosuppressive agents
Product containing precisely teriflunomide 14 milligram/1 each conventional release oral tablet (clinical drug)
adult
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical

---
https://www.has-sante.fr/jcms/p_3330878/fr/aubagio-teriflunomide-sep-recurrentes-remittentes
2022
France
evaluation of the transparency committee
recurrence
traction
indicators
indication of
multiple sclerosis
teriflunomide
teriflunomide
teriflunomide
indicators and reagents

---
https://ansm.sante.fr/dossiers-thematiques/medicaments-et-grossesse/traitement-de-la-sclerose-en-plaques-pendant-la-grossesse
2021
false
false
false
France
French
pregnancy
multiple sclerosis
Pregnant People
teriflunomide
patients guideline
drug information
breast feeding
immunosuppressive agents

---
https://www.has-sante.fr/jcms/p_3117100/fr/aubagio
2019
false
false
false
France
teriflunomide
treatment outcome
multiple sclerosis, relapsing-remitting
evaluation of the transparency committee
administration, oral
immunologic factors
adult
teriflunomide
crotonates
toluidines

---
http://www.has-sante.fr/portail/jcms/c_2722045/fr/aubagio
2016
false
false
false
France
French
immunologic factors
teriflunomide
teriflunomide
administration, oral
adult
multiple sclerosis, relapsing-remitting
immunomodulators
treatment outcome
insurance, health, reimbursement
teriflunomide
immunomodulators
immunologic factors
evaluation of the transparency committee
crotonates
toluidines
crotonates
toluidines

---
Summary Basis of Decision (SBD) for Aubagio
Teriflunomide, 14 mg, tablet, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?linkID=SBD00274
2014
false
Canada
French
English
teriflunomide
teriflunomide
drug approval
canada
administration, oral
teriflunomide
adult
immunologic factors
immunologic factors
multiple sclerosis, relapsing-remitting
treatment outcome
drug evaluation
risk assessment
oxidoreductases acting on CH-CH group donors
crotonates
crotonates
toluidines
toluidines
drug information
Dihydroorotate Dehydrogenase

---
http://www.meddispar.fr/Medicaments/AUBAGIO-14-B-28/(type)/letter/(value)/A/(cip)/3400927499890
2014
false
true
false
France
French
drug information
administration, oral
drug prescriptions
legislation, drug
teriflunomide
teriflunomide
multiple sclerosis, relapsing-remitting
crotonates
toluidines

---
http://www.has-sante.fr/portail/jcms/c_1730041/fr/aubagio-teriflunomide-immunomodulateur
2014
false
false
false
France
French
immunologic factors
teriflunomide
teriflunomide
administration, oral
adult
multiple sclerosis, relapsing-remitting
immunomodulators
treatment outcome
insurance, health, reimbursement
teriflunomide
immunomodulators
immunologic factors
evaluation of the transparency committee
guidelines for drug use
crotonates
toluidines
crotonates
toluidines

---
https://www.ema.europa.eu/medicines/human/EPAR/Aubagio
2013
false
United Kingdom
English
French
teriflunomide
teriflunomide
teriflunomide
drug approval
europe
treatment outcome
package leaflet
summary of product characteristics
drug evaluation
syndication feed
adult
multiple sclerosis, relapsing-remitting
administration, oral
immunologic factors
immunologic factors
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
oxidoreductases acting on CH-CH group donors
crotonates
crotonates
toluidines
toluidines
Dihydroorotate Dehydrogenase

---
http://www.cochrane.org/fr/CD009882
2012
United Kingdom
France
French
teriflunomide
review of literature
multiple sclerosis
treatment outcome
crotonates
toluidines
teriflunomide
french abstract

---
Nous contacter.
02/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.